Janssen to Develop Assays on Biocartis MDx Platform | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Janssen Pharmaceutica, part of Johnson & Johnson's Janssen Pharmaceutical division, will develop assays on the Biocartis molecular diagnostics system, Biocartis said today.

Under the agreement, Janssen and J&J's Ortho-Clinical Diagnostics group will have worldwide exclusive rights to develop and commercialize assays on the Biocartis platform in the fields of neurological disease and certain viral infectious diseases.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.